• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Patterson Companies Inc.

    4/22/25 9:00:17 AM ET
    $PDCO
    Medical Specialities
    Health Care
    Get the next $PDCO alert in real time by email
    8-K
    Common Stock, par value $.01 PDCO NASDAQ false 0000891024 0000891024 2025-04-17 2025-04-17
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported)

    April 22, 2025 (April 17, 2025)

     

     

    PATTERSON COMPANIES, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Minnesota   0-20572   41-0886515

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    1031 Mendota Heights Road

    St. Paul, Minnesota 55120

    (Address of Principal Executive Offices, including Zip Code)

    (651) 686-1600

    (Registrant’s Telephone Number, including Area Code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    None   None   None

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On April 22, 2025, Patterson Companies, Inc. (the “Company”) announced that, in connection with the closing of the Company’s previously disclosed acquisition by Patient Square Capital, a dedicated health care investment firm, Robert Rajalingam was appointed as the new Chief Executive Officer of the Company effective April 17, 2025. Donald Zurbay, who previously served as Chief Executive Officer and a director of the Company, ceased to serve in such roles effective the same day. Mr. Zurbay will continue to support the Company on a transitional basis.

    Mr. Rajalingam has more than 25 years of experience in health care management, most recently as President of Cardinal Health’s U.S. Medical Products and Distribution business since 2021, where he led significant transformation in the business. Mr. Rajalingam previously served as President of Cardinal Health’s U.S. Sales, Medical Solutions business from 2019 to 2021. Mr. Rajalingam also serves on the boards of directors of Nonin Medical, Inc., a medical device manufacturer, and Strategic Marketplace Initiative, a community for healthcare providers and suppliers. Mr. Rajalingam has a Bachelor of Science in Economics and Biomedical Engineering from Duke University and a Master of Business Administration from Stanford University.

    Mr. Zurbay’s departure was not a result of any disagreement between the Company and any of the directors on any matter relating to the Company’s operations, policies or practices.

    Mr. Rajalingam is not related to any director or officer of the Company or any person nominated or chosen by the Company to become a director or officer. There are no arrangements or understandings between Mr. Rajalingam and any other person pursuant to which he will serve as an officer. There are no transactions in which Mr. Rajalingam has an interest requiring disclosure under Item 404(a) of Regulation S-K.

    A copy of the related press release, which the Company issued on April 22, 2025, is attached as Exhibit 99.1 hereto.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits:

    EXHIBIT INDEX

     

    Exhibit

    No.

       Description
    99.1    Press Release of Patterson Companies, Inc., dated April 22, 2025.
    104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    PATTERSON COMPANIES, INC.
    By:  

    /s/ Les B. Korsh

      Les B. Korsh
      Chief Legal Officer and Corporate Secretary

    Dated: April 22, 2025

    Get the next $PDCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDCO

    DatePrice TargetRatingAnalyst
    12/4/2024$23.00Neutral
    Mizuho
    2/29/2024$34.00 → $28.00Overweight → Neutral
    Piper Sandler
    2/26/2024$36.00Outperform
    Leerink Partners
    5/13/2022$36.00Outperform
    Credit Suisse
    3/3/2022$30.00 → $32.00Equal-Weight
    Morgan Stanley
    1/31/2022$30.00Equal-Weight
    Morgan Stanley
    10/1/2021$38.00Outperform
    Credit Suisse
    More analyst ratings

    $PDCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:15:41 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:08:45 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:06:32 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Patterson Companies with a new price target

      Mizuho initiated coverage of Patterson Companies with a rating of Neutral and set a new price target of $23.00

      12/4/24 7:46:30 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Patterson Companies from Overweight to Neutral and set a new price target of $28.00 from $34.00 previously

      2/29/24 6:36:04 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Patterson Companies with a new price target

      Leerink Partners initiated coverage of Patterson Companies with a rating of Outperform and set a new price target of $36.00

      2/26/24 8:10:56 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies, Inc. Shareholders Approve Acquisition by Patient Square Capital

      Patterson Companies, Inc. (NASDAQ:PDCO), a value-added specialty distributor serving the U.S. and Canadian dental supply markets and the U.S., Canadian and U.K. animal health supply markets, today announced that its shareholders approved at a special meeting the acquisition of Patterson by Patient Square Capital, a dedicated health care investment firm. Don Zurbay, Patterson's President and Chief Executive Officer, said, "I would like to express my gratitude to the Patterson shareholders for their support today, and throughout this transaction process. The Patterson team is excited about this partnership with Patient Square Capital and beginning our next chapter as a private company. We be

      4/1/25 1:00:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Patterson Companies Inc.

      15-12G - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/28/25 10:30:38 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Patterson Companies Inc.

      8-K - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/22/25 9:00:17 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Patterson Companies Inc.

      S-8 POS - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/17/25 9:23:38 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies Announces Dental Leadership Appointment

      Kristin Dietzler Named Dental President Patterson Companies Inc. (NASDAQ:PDCO) announced the appointment of Kristin Dietzler as Patterson Dental's North American president. Dietzler brings extensive expertise in adjacent healthcare companies with a proven track record of success in optimizing results. She will report to Kevin Pohlman, chief operating officer of Patterson Companies, and she will be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241023782217/en/Kristin Dietzler Named Patterson Dental President (Photo: Business Wire) Dietzler joins Patterson Dental with nearly 30

      10/23/24 6:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Announces Dental Leadership Transition

      Patterson Companies, Inc. (NASDAQ:PDCO) today announced that it has initiated a search for a new leader for its Dental segment. Tim Rogan, who has served as President of Patterson Dental since 2021, has stepped down from his role, effective immediately, and agreed to serve as an advisor to the Company in the short term to facilitate a smooth transition. The Dental segment will continue to report to Chief Operating Officer, Kevin Pohlman. "Our dental business has made significant progress to further enhance our value proposition and differentiate Patterson as the partner of choice for our customers. After careful consideration, we determined that a leadership transition will best position

      5/10/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Financials

    Live finance-specific insights

    See more
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Second Quarter Operating Results

      Second quarter reported net sales increased 1.3 percent year-over-year to $1.67 billion, and internal sales increased 0.6 percent. Delivered second quarter GAAP earnings of $0.30 per diluted share and adjusted earnings1 of $0.47 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $96.2 million to shareholders in the form of cash dividends and share repurchases through the first six months of fiscal 2025. Revises fiscal 2025 GAAP earnings guidance range to $1.83 to $1.93 per diluted share and adjusted earnings1 guidance range to $2.25 to $2.35 per diluted share. Company

      12/5/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Fiscal 2025 Second Quarter Conference Call Scheduled for Thursday, December 5, 2024

      Patterson Companies (NASDAQ:PDCO) today announced that it will hold its fiscal 2025 second-quarter conference call on Thursday, December 5, 2024, at 7:30 a.m. CT (8:30 a.m. ET). The company's earnings release will be issued that morning before the market opens. To access the live webcast, go to the investor relations section of the company's website, www.PattersonCompanies.com. An audio replay of the fiscal 2025 second-quarter conference call will also be available for one week. To access the audio replay, please pre-register at https://registrations.events/direct/Q4I672812531 to receive a unique access code to access and listen to the audio playback. About Patterson Companies Inc. Pa

      11/27/24 7:19:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/13/24 5:12:03 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      12/8/23 4:16:31 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/14/23 12:37:55 PM ET
      $PDCO
      Medical Specialities
      Health Care